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ABSTRACT 
A late recurrence of Wilms tumour 23 years after the primary diagnosis is described.  
The primary tumour occurred in a 10 months old girl and showed various degrees of 
differentiation, including skeletal muscle phenotype. A postoperative chemotherapy was 
performed. Twenty-three years after surgery, the tumour relapsed: the lesion was 
exclusively composed of mature skeletal muscle elements (diffuse and intense desmin 
reactivity) derived from the primary tumour, as confirmed by WT1 immunoreactivity.  
Chemotherapy and radiotherapy have been reported previously to ablate the immature 
components of Wilms tumour; especially, chemotherapy can modify the histological type 
reducing the immature elements while leaving mature cells un-affected. We can 
hypothesise that both, the morphological and molecular features of the tumour as well as 
the effect of therapy can influence a tumour-relapse in Wilms tumour. The latter results in 
a high degree of differentiation and a long disease-free interval after the first diagnosis. 
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INTRODUCTION 
Wilms tumour (WT) is the most common primary malignant renal tumour in children.  
The association of chemotherapy and radiotherapy to radical nephrectomy has increased 
the overall survival rate up to 85-90% [3,6];however, in spite of these therapeutic 
improvements, tumour relapses in a subset of patients (15-20%) [12].Numerous studies 
have demonstrated that the risk of recurrence can be associated to different features such 
as histological tumour pattern and loss of heterozygosis (LOH) at 1p and/or 16q, as well as 
gain of chromosome 1 and other recently described alterations [8,18,7,14]. The recurrence 
risk is greater within the first 2 years after primary diagnosis (in these patients the 
percentage of survival approximaly ranges from 24% to 43%) but late relapses have 
occasionally been reported [1,10]. 
We here report a case of late recurrence of Wilms tumour, 23 years after primary 
diagnosis. 
 
CLINICAL HISTORY 
In October 2005 a 23 years-old female came to medical attention for abdominal recurrent 
pain and occlusive status. Physical examination revealed an abdominal soft mass in the 
peri-umbilical region; hematochemical analysis showed normal values for gastrointestinal 
cancer-associated antigens, carcinoembryonic antigen (CEA), α-phetoprotein (αFP), 
carbohydrate antigen 19.9 (CA 19.9) and carbohydrate antigen 125 (CA 125). Abdominal 
ultrasonography, computed tomography (CT scan) and magnetic resonance imaging (MRI) 
disclosed two masses: the first one was placed in the right peri-umbilical region whereas 
the second one, placed in left retroperitoneal space, caused compression of the wall of the 
small bowel. A tomography emission of positron (PET scan) showed no signal 
accumulation. The patient underwent surgical removal of the abdominal and 
retroperitoneal masses. Nine months after surgical removal the patient is disease-free. 
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A left nephrectomy with surgical removal of a Wilms tumour had been performed 23 years 
before (in September 1982). An histopathological diagnosis of Wilms tumour (G2, 
favourable histology) with differentiation towards epithelial (tubular elements), 
blastematous and rhabdomyoblastic features was made. No preoperative chemotherapy 
was performed, but following surgery the patient underwent cycles of chemotherapy with 
actinomicin D and vincristine. The subsequently follow-up was negative for the following 
23 years.  
 
MATERIAL AND METHODS 
The surgical material was totally examined and accurately sampled. The surgical 
specimens of both masses were fixed in 4% buffered formaldehyde and embedded in 
paraffin and the routine histological sections of 3µm were prepared and stained with 
haematoxylin and eosin (H&E). Additional sections, collected on poly-L-lysine coated 
slides, were used for the immunohistochemistry analysis. Immunohistochemical reactions 
using antibodies anti-desmin (monoclonal antibody, clone D33, diluted 1:50, DAKO 
Glostrup Denmark), anti-smooth muscle actin (monoclonal antibody, clone 1A4, pre-
diluted, Ventana-Diapath, Tucson, AZ, USA) and Wilms tumour 1 Protein (WT-1) 
(monoclonal antibody, clone 6F-H2, diluted 1:20, IMGENEX) were performed in an 
automated immunostainer (Ventana BenchMark AutoStainer, Ventana Medical Systems, 
Tucson, AZ, USA). 
  
RESULTS 
Pathological findings 
A left nephrectomy with excision of the renal hilum lymph-node and the omentum was 
performed in September 1982. Grossly, the surgical specimen measured 14x12x8 cm and 
displayed a pale grey appearance with diffuse hemorrhagic areas; at the cut surface two 
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different nodes were present: the first one, measuring 6 cm, close to the renal hilum and 
the second one, measuring 9 cm, localized at the inferior renal pole. At the histological 
level (the slides were collected and revised in our Institute) the lesion showed various 
degrees of cell differentiation within the different cell components (epithelial, blastematous 
and stromal). The tumour cells were organized in nodes either isolated or confluent in 
clusters and diffusely invading the residual renal parenchyma (fig.1 a); focally, epithelial 
cells assumed a pseudo-glandular architecture (fig.1 b, c). The mesenchymal tumour cells 
were elongated or rounded with a scanty cytoplasm and voluminous and iper-chromatic 
nuclei. In some areas, representing about 10% of the tumour, skeletal muscle with 
elongated cells showing an intra-cytoplasmatic cross-striations was present (fig.1 d). No 
evidence of nephrogenic rests was found. The renal capsule and the omentum appeared 
infiltrated by proliferating neoplastic cells. The renal hilum lymph-node examined did not 
display any metastatic cells. A confirmatory diagnosis of Wilms tumour (G2, favourable 
histology) with epithelial, blastematous and rhabdomyoblastic differentiation was made 
(Stage III). 
The lesion removed in October 2005 was represented by two different surgical specimens: 
a well circumscribed mass of abdominal wall, measuring cm 14x11x2 and a retroperitoneal 
mass adjacent the small bowel, measuring cm 11,5x9x3,5. Macroscopically, both lesions 
were lobulated, encapsulated and showed a stiff-elastic consistency. At cut-surface, both 
lesions appeared yellow-whitish in colour and with a fasciculated appearance. 
Microscopically, both lesions showed an exclusive benign-appearing stroma component 
with mature skeletal muscle; no evidence of immature elements or nephrogenic rests was 
found (fig.2 a, b). In the lesion adherent to the small bowel, such proliferation of mature 
skeletal muscle elements was not displaying any infiltrating pattern towards the bowel wall. 
Such elements were arranged in bundles separated by fibrous tissue and presented intra-
cytoplasmatic cross-striations, an eosinophilic cytoplasm and a peripheral nuclear location 
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(fig.2 b). Necrosis was absent. Immunohistochemical studies showed diffuse and intense 
desmin (fig.2 d) and WT-1 (fig. 2 c) reactivity. Cells were negative for smooth muscle 
actin, (which was positive in vascular structures only) and had a low proliferation index 
(Ki67<1%). 
Altogether, the morphological and immunohistochemical features displayed by the two 
lesions, together with the previous history of Wilms tumour and the lack of any infiltrating 
or invading growth pattern addressed to a diagnosis of late recurrence of Wilms tumour 
with exclusive mature skeletal-muscle component.  
 
DISCUSSION 
Approximately 15-20% of cases of Wilms tumour relapse, more frequently within the first 
2-5 years following the primary diagnosis; in these cases, the risk of recurrence is mainly 
related to the morphological and molecular features of the previous tumour [12,8,18,7,14].  
Late recurrences (>5 years after primary diagnosis) of Wilms tumour are very rare 
[16,11,2,15,13,4,5] and in all described cases, but one, similar histological patterns 
between the original and the relapsing tumour are reported with a persistence of immature 
cells, blastematous elements or nephrogenic rests [16,11,2,15,13,4]. In one case only, 
which was a late (23 years) recurrence, differentiated epithelial cells in absence of 
immature elements (in contrast of the original tumour showing predominantly blastematous 
and immature elements) were reported [5]. The case here described showed two well 
circumscribed lesions with a stiff-elastic consistency, exclusively composed of mature 
skeletal muscle elements derived from the primary tumour, as confirmed by WT1 
immunoreactivity. In addition, absence of necrosis and pleomorphism and the low 
proliferation index (<1%) further excluded the possible differential diagnosis with a 
sarcomatous lesion. 
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Zuppan and co-workers recently stressed that preoperative chemotherapy is associated to 
changes of the histological features, thus creating an ambiguity on Wilms tumour staging 
according to tumour response [19]. They outlined that the therapy effect is variable 
depending on the different histological subtypes of Wilms tumour: some tumours show 
little therapy effects with persistence of abundant and proliferating blastema elements, 
others show an “atrophic pattern”. Sometimes, the loss of most embrional elements 
induced by therapy is accompanied by persistence of mature heterotopic elements such 
as mature skeletal muscle, cartilage or adipose tissue [19]. Blastematous cells usually 
show a dramatic response leading to necrosis, whereas mature tubular and skeletal 
muscle cells tend to persist [17].  
We can hypothesise that since preoperative chemotherapy is able to enhance the grade of 
differentiation, postoperative chemotherapy as well could induce “tumour maturation” and 
that in our patient a maturation of residual tumour cells occurred. 
Confirmatory evidence to such hypothesis is found in the literature, where a lesion entirely 
represented by mature skeletal muscle, similar to our relapsing tumour, was reported in 
the controlateral kidney in two children treated with radiotherapy for Wilms tumour 
following surgery [9]. 
Evidence is therefore accruing that chemotherapy and radiotherapy can ablate the 
immature components of tumour, operating a sort of selection leading, in some cases, to 
the exclusive persistence of mature elements [17].  
In conclusion, different factors can affect a possible tumour-relapse in Wilms tumour: the 
morphological and molecular features of the tumour  (LOH at 1p and/or 16q, gain 1q, etc.) 
and/or the therapy effect on the tumour itself. Also, we can consistently hypothesize that 
two different types of Wilms tumour recurrences can be recognised: a more 
undifferentiated one, which usually appears after a short disease-free interval and could be 
associated to a more aggressive tumour with specific genetic alterations and a worse 
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prognosis, and a second type, eventually related to therapy, presenting a high degree of 
differentiation and a long disease-free interval after the first diagnosis. The last one 
generally has an indolent course. The peculiarity of our case consists on the long disease-
free interval from the primary tumour, as well as on its morphological well differentiated 
features probably induced by chemotherapy. 
 
 
 8
 REFERENCES 
1. Campbell AD, Cohn SL, Reynolds M, Seshadri R, Morgan E, Geissler G, 
Rademaker A, Marymount M, Kalapurakal J, Haut PR, Duerst R, Kletzel M (2004) 
Treatment of relapsed Wilms' tumor with high-dose therapy and autologous 
hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital. J 
Clin Oncol 22:2885-90 
2. Clausen N (1982) Late recurrence of Wilms’tumor Med Pediatr Oncol 10:557-561 
3. Dome JS, Liu T, Krasin M, Lott L, Shearer P, Daw NC, Billups CA, Wilimas JA 
(2002) Improved survival for patients with recurrent Wilms tumor: the experience 
at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol 24:192-8 
4. Gibson PJ, Vadeboncoeur CM, Johnston DL (2005) Relapse of Wilms' tumor 13 
years after original diagnosis. J Pediatr Hematol Oncol 27:293-4 
5. Gottesman JE, Pellettiere EV, Kilmer W (1981) Recurrence of Wilms tumor 
twenty-three years later.  Urology 17:268-9 
6. Green DM (2004) The treatment of stages I-IV favorable histology Wilms' tumor. J 
Clin Oncol 22:1366-72 
7. Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger 
RC, Haase GM, D'Angio GJ, Donaldson M, Coppes MJ, Malogolowkin M, Shearer 
P, Thomas PR, Macklis R, Tomlinson G, Huff V, Green DM; National Wilms 
Tumor Study Group (2005) Loss of heterozygosity for chromosomes 1p and 16q 
is an adverse prognostic factor in favorable-histology Wilms tumor: a report from 
the National Wilms Tumor Study Group. J Clin Oncol 23:7312-21 
8. Hing S, Lu YJ, Summersgill B, King-Underwood L, Nicholson J, Grundy P, Grundy 
R, Gessler M, Shipley J, Pritchard-Jones K (2001) Gain of 1q is associated with 
adverse outcome in favorable histology Wilms' tumors. Am J Pathol 158:393-8 
 9
9. Hughson MD, Hennigar GR, Othersen HB Jr (1976) Cytodifferentiated renal 
tumors occurring with Wilms' tumors of the opposite kidneys: report of two cases. 
Am J Clin Pathol 66:376-89 
10. Kalapurakal JA, Dome JS, Perlman EJ, Malogolowkin M, Haase GM, Grundy P, 
Coppes MJ  (2004) Management of Wilms' tumour: current practice and future 
goals. Lancet Oncol 5:37-46 
11. Kim TH, Zaatari GS, Baum ES, Jaffe N, Cushing B, Chard RL Jr, Zwiren GT, 
Beckwith JB (1985) Recurrence of Wilms’ tumor after apparent cure. J Pediatr 
107:44-49 
12. Li W, Kessler P, Yeger H, Alami J, Reeve AE, Heathcott R, Skeen J, Williams BR 
(2005) A gene expression signature for relapse of primary Wilms tumors. Cancer 
Res 65:2592-601 
13. Mikraki V, Yiannoulopoulos G, Moschovi M, Constantinidou-Van Vliet C, 
Tzortzatou-Stathopoulou F (1996) Late local recurrence of Wilms’ tumor. Medical 
and Pediatric Oncology 26:71 
14. Natrajan R, Williams RD, Hing SN, Mackay A, Reis-Filho JS, Fenwick K, Iravani 
M, Valgeirsson H, Grigoriadis A, Langford CF, Dovey O, Gregory SG, Weber BL, 
Ashworth A, Grundy PE, Pritchard-Jones K, Jones C (2006) Array CGH profiling 
of favourable histology Wilms tumours reveals novel gains and losses associated 
with relapse. J Pathol 210:49-58 
15. Perilongo G, Carli M, Fassina A, Colleselli P, Cocito MG, Rebuffi L (1984) 
Recidiva tardiva di tumore di Wilms. Pediatr Med Chir 6:447-448 
16. Soledad Gallego-Melcon, Jose Sanchez de Toledo, Divina Doste, Diana Lopez, 
FernandaMoraga, Carlos Rodriguez, Teresa Vidal and Joaquim Bellmunt (1994) 
Late recurrent metastasis in Wilms’ tumor. Medical and Pediatric oncology 
23:158-161 
 10
17. William M. Murphy, David j. Grignon, Elizabeth j. Perlman (ed) (2004) Tumors of 
the Kidney, Bladder, and Related Urinary Structures. Armed Forces Institute of 
Pathology (AFIP)  Washington DC, USA 
18. Williams RD, Hing SN, Greer BT, Whiteford CC, Wei JS, Natrajan R, Kelsey A, 
Rogers S, Campbell C, Pritchard-Jones K, Khan J (2004) Prognostic classification 
of relapsing favorable histology Wilms tumor using cDNA microarray expression 
profiling and support vector machines. Genes Chromosomes Cancer 41:65-79 
19. Zuppan CW, Beckwith JB, Weeks DA, Luckey DW, Pringle KC (1991) The effect 
of preoperative therapy on the histologic features of Wilms' tumor. An analysis of 
cases from the Third National Wilms' Tumor Study. Cancer 68:385-94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 11
LEGENDS 
Figure 1: Histological features of the primary Wilms tumour (surgical removed in 
September 1982). The tumour showed the coexistence at epithelial (tubular elements) 
blastematous (a 10x, b40x, c 20x), and rhabdomyoblastic (d 40x) elements; areas of 
necrosis were also present. 
Figure 2: Histological and immunophenotypical features of the Wilms tumour 
recurrence (surgical removed in October 2005). The late relapse of Wilms tumour 
showed an exclusive benign-appearing stroma with the skeletal muscle component without 
the evidence of immature elements or nephrogenic rests (a 10x, b 20x). The lesion was 
immunoreactive for WT-1 (c 40x) and desmin in neoplastic muscular cells (d 20x).  
 
 
 
 
 
 
 
 
 
 12
